当前位置:
首页
>
产品中心 >
clinical_research >
absoluteantibody/Ab00450-1.4 Anti-CD4 [CE9.1 (Clenoliximab)]/Ab00450-1.4/ 200 µg
absoluteantibody/Ab00450-1.4 Anti-CD4 [CE9.1 (Clenoliximab)]/Ab00450-1.4/ 200 µg
商品编号:
Ab00450-1.4
品牌:
absoluteantibody
市场价:
¥5400.00
美元价:
3240.00
产品分类:
临床研究
公司分类:
clinical_research
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
Description: Recombinant monoclonal antibody to CD4 . Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma CE9.1 (Clenoliximab). This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.
Clone Number: CE9.1 (Clenoliximab)
UniProt Accession Number of Target Protein: P01730
Alternative Name(s) of Target: p55; T cell surface antign T4/Leu-3.
Published Application(s): ELISA; FC; Block; SPR; IHC
Published Species Reactivity: Human; chimpanzee
Immunogen: Domain 1 of human CD4.
Specificity: The antibody binds to human CD4 with a Kd of 1.0 nM and an ED50 of 0.2 ug/ml.
Application Notes: The antibody binds specifically to CD4, a molecule which is part of the immunolgobulin super-family, expressed on the surface of helper T cells. The CD4 molecule acts as a co-receptor in the activation of T cells, aiding the interaction between the TCR and MHC II of the antigen-presenting cell. The antibody is classified as 'primatized', as the variable regions of the light and heavy chains are obtained from primates, while the lamda light chain and γ4 heavy chain constant domains are human. The antibody was engineered from the primatized IgG1 monoclonal antibody Keliximab by substituting two key residues. The role of the antibody as an immunosuppressor has been tested in vivo, by intravenous administration in chimpanzees and human volunteers. The antibody reached Phase II clinical trials with Biogen-Idec.
Antibody First Published in:
Newman et al. Primatization of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Biotechnology (NY). 1992 Nov;10(11):1455-60. PMID:1369023 Note on publication: Describes the method of producing 'primatized' antibodies, where immunoglobulin genes from cynomolgus monkeys immunised with human CD4 are isolated, amplified and then cloned. The antibodies generated are against the CD4 molecule expressed on the surface of helper T cells, and are tested for both in vitro and in vivo use.
Concentration: See vial label.
Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic
procedures for humans or animals.NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques.
Species and Isotype: Mouse IgG1, Fc Silent™, lambdaClone Number: CE9.1 (Clenoliximab)
UniProt Accession Number of Target Protein: P01730
Alternative Name(s) of Target: p55; T cell surface antign T4/Leu-3.
Published Application(s): ELISA; FC; Block; SPR; IHC
Published Species Reactivity: Human; chimpanzee
Immunogen: Domain 1 of human CD4.
Specificity: The antibody binds to human CD4 with a Kd of 1.0 nM and an ED50 of 0.2 ug/ml.
Application Notes: The antibody binds specifically to CD4, a molecule which is part of the immunolgobulin super-family, expressed on the surface of helper T cells. The CD4 molecule acts as a co-receptor in the activation of T cells, aiding the interaction between the TCR and MHC II of the antigen-presenting cell. The antibody is classified as 'primatized', as the variable regions of the light and heavy chains are obtained from primates, while the lamda light chain and γ4 heavy chain constant domains are human. The antibody was engineered from the primatized IgG1 monoclonal antibody Keliximab by substituting two key residues. The role of the antibody as an immunosuppressor has been tested in vivo, by intravenous administration in chimpanzees and human volunteers. The antibody reached Phase II clinical trials with Biogen-Idec.
Antibody First Published in:
Newman et al. Primatization of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Biotechnology (NY). 1992 Nov;10(11):1455-60. PMID:1369023 Note on publication: Describes the method of producing 'primatized' antibodies, where immunoglobulin genes from cynomolgus monkeys immunised with human CD4 are isolated, amplified and then cloned. The antibodies generated are against the CD4 molecule expressed on the surface of helper T cells, and are tested for both in vitro and in vivo use.
Product Form
Purification: Protein A affinity purified Supplied in: PBS only.
Storage Recommendation: Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°CConcentration: See vial label.
品牌介绍
Absolute antibody本公司服务于抗体测序、制造和工程服务提供给所有抗体使用者和不断增长的抗体。Absolute Antibody Ltd was founded in Oxford, UK, in August 2012, with the vision that all antibody users should be able to use recombinant antibodies, which are absolutely defined by their amino acid sequence. This view gained support in 2015 with a Comment in Nature magazine by Bradbury and Pluckthun (+110 co-signatories) – “Reproducibility: Standardize antibodies used in research“. Rather than creating entirely new antibodies (or antibody-like molecules), we are building a catalog by taking existing antibodies (often from hybridomas) then manufacturing them in a superior way and improving their usefulness by engineering.品牌货号名称规格absoluteantibody21 E11Anti-Api m 21 kitabsoluteantibodyBAB2Anti-Bet v 1 1 kitabsoluteantibodyBAB3Anti-Bet v 11 kitabsoluteantibodyBAB4Anti-Bet v 11 kitabsoluteantibodyBAB5Anti-Bet v 1 1 kitabsoluteantibodyBV16Anti-Bet v 1 1 kitabsoluteantibodyM0418Anti-Bet v 11 kitabsoluteantibody4C3Anti-Bla g 2 1 kitabsoluteantibody7C11Anti-Bla g 21 kitabsoluteantibodyD1Anti-Bos d 5 1 kitabsoluteantibody6A8Anti-Der f 11 kitabsoluteantibody10B9Anti-Der p 11 kitabsoluteantibody5H8Anti-Der p 11 kitabsoluteantibody4C1Anti-Neurotoxin AahII1 kitabsoluteantibodyH10Anti-Der p 21 kit
品牌分类
关注表位标记
Primary Antibodies
Recombinant Antibodies from Human Patients
Anti-Allergen Antibodies
多标签控制蛋白
Recombinant Isotype Controls
抗过敏原抗体
重组F4/80克隆CI:A3-1
体内研究用重组抗体
联络我们
服务热线:4000-520-616
(限工作日9:00-18:00)
QQ :1570468124
手机:18915418616